Standard

Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. / Zastrozhin, Michael S.; Skryabin, Valentin Y.; Torrado, Marco; Petrovna, Anastasiya; Sorokin, Alexander S.; Grishina, Elena A.; Ryzhikova, Kristina A.; Bedina, Inessa A.; Buzik, Oleg Z.; Chumakov, Egor M.; Savchenko, Ludmila M.; Brun, Evgeny A.; Sychev, Dmitry A.

в: Pharmacogenomics, Том 21, № 2, 01.2020, стр. 111-123.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Zastrozhin, MS, Skryabin, VY, Torrado, M, Petrovna, A, Sorokin, AS, Grishina, EA, Ryzhikova, KA, Bedina, IA, Buzik, OZ, Chumakov, EM, Savchenko, LM, Brun, EA & Sychev, DA 2020, 'Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder', Pharmacogenomics, Том. 21, № 2, стр. 111-123. https://doi.org/10.2217/pgs-2019-0019, https://doi.org/10.2217/pgs-2019-0019

APA

Zastrozhin, M. S., Skryabin, V. Y., Torrado, M., Petrovna, A., Sorokin, A. S., Grishina, E. A., Ryzhikova, K. A., Bedina, I. A., Buzik, O. Z., Chumakov, E. M., Savchenko, L. M., Brun, E. A., & Sychev, D. A. (2020). Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. Pharmacogenomics, 21(2), 111-123. https://doi.org/10.2217/pgs-2019-0019, https://doi.org/10.2217/pgs-2019-0019

Vancouver

Zastrozhin MS, Skryabin VY, Torrado M, Petrovna A, Sorokin AS, Grishina EA и пр. Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. Pharmacogenomics. 2020 Янв.;21(2):111-123. https://doi.org/10.2217/pgs-2019-0019, https://doi.org/10.2217/pgs-2019-0019

Author

Zastrozhin, Michael S. ; Skryabin, Valentin Y. ; Torrado, Marco ; Petrovna, Anastasiya ; Sorokin, Alexander S. ; Grishina, Elena A. ; Ryzhikova, Kristina A. ; Bedina, Inessa A. ; Buzik, Oleg Z. ; Chumakov, Egor M. ; Savchenko, Ludmila M. ; Brun, Evgeny A. ; Sychev, Dmitry A. / Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. в: Pharmacogenomics. 2020 ; Том 21, № 2. стр. 111-123.

BibTeX

@article{db0b714fdc0745639fd731b85a0c6da3,
title = "Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder",
abstract = "Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-Time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.",
keywords = "alcohol addiction, anxiety disorders, benzodiazepines, biotransformation, bromodihydrochlorobenzodiazepine, personalized medicine, phenazepam, Anxiety Disorders/drug therapy, Anti-Anxiety Agents/administration & dosage, Humans, Genotype, Male, Benzodiazepines/administration & dosage, Adult, Cytochrome P-450 CYP2C19/genetics, Female, Alcoholism/genetics, SUBSTANCE-ABUSE, CYP2C19, MOOD, CYP2D6, MIDAZOLAM, DEPRESSION, GENETIC POLYMORPHISMS, HALOPERIDOL, BENZODIAZEPINES, RESPONSES, bromodihydrochloroben-zodiazepine",
author = "Zastrozhin, {Michael S.} and Skryabin, {Valentin Y.} and Marco Torrado and Anastasiya Petrovna and Sorokin, {Alexander S.} and Grishina, {Elena A.} and Ryzhikova, {Kristina A.} and Bedina, {Inessa A.} and Buzik, {Oleg Z.} and Chumakov, {Egor M.} and Savchenko, {Ludmila M.} and Brun, {Evgeny A.} and Sychev, {Dmitry A.}",
year = "2020",
month = jan,
doi = "10.2217/pgs-2019-0019",
language = "English",
volume = "21",
pages = "111--123",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "2",

}

RIS

TY - JOUR

T1 - Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder

AU - Zastrozhin, Michael S.

AU - Skryabin, Valentin Y.

AU - Torrado, Marco

AU - Petrovna, Anastasiya

AU - Sorokin, Alexander S.

AU - Grishina, Elena A.

AU - Ryzhikova, Kristina A.

AU - Bedina, Inessa A.

AU - Buzik, Oleg Z.

AU - Chumakov, Egor M.

AU - Savchenko, Ludmila M.

AU - Brun, Evgeny A.

AU - Sychev, Dmitry A.

PY - 2020/1

Y1 - 2020/1

N2 - Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-Time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.

AB - Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-Time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.

KW - alcohol addiction

KW - anxiety disorders

KW - benzodiazepines

KW - biotransformation

KW - bromodihydrochlorobenzodiazepine

KW - personalized medicine

KW - phenazepam

KW - Anxiety Disorders/drug therapy

KW - Anti-Anxiety Agents/administration & dosage

KW - Humans

KW - Genotype

KW - Male

KW - Benzodiazepines/administration & dosage

KW - Adult

KW - Cytochrome P-450 CYP2C19/genetics

KW - Female

KW - Alcoholism/genetics

KW - SUBSTANCE-ABUSE

KW - CYP2C19

KW - MOOD

KW - CYP2D6

KW - MIDAZOLAM

KW - DEPRESSION

KW - GENETIC POLYMORPHISMS

KW - HALOPERIDOL

KW - BENZODIAZEPINES

KW - RESPONSES

KW - bromodihydrochloroben-zodiazepine

UR - http://www.scopus.com/inward/record.url?scp=85077990650&partnerID=8YFLogxK

UR - http://www.mendeley.com/catalogue/effects-cyp2c192-polymorphisms-efficacy-safety-phenazepam-patients-anxiety-disorder-comorbid-alcohol

UR - https://www.mendeley.com/catalogue/c91a33d2-b26d-362d-a5a9-8883489d99d6/

U2 - 10.2217/pgs-2019-0019

DO - 10.2217/pgs-2019-0019

M3 - Article

C2 - 31957548

AN - SCOPUS:85077990650

VL - 21

SP - 111

EP - 123

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 2

ER -

ID: 50738937